Fund Overview
The Barwon Healthcare Property Fund is an open-ended fund which invests nationally in healthcare real estate. The Fund’s assets include a variety of primary and secondary care facilities, tenanted by some of Australia’s largest private medical providers, in addition to State Government tenants. The Fund targets acquisitions that provide wholesale investors with target quarterly distributions of approximately 5% – 6% p.a. and the potential for capital growth, targeting a total return of 8%-10% p.a. net of fees.
The Fund holds a well-diversified portfolio of quality healthcare properties including:
The properties are predominantly located in major metropolitan and regional cities across Australia.
Investment Team
Research

Performance
Fund Name | Unit Price (CUM) | Income Return IDP p.a. | Capital Return IDP p.a. | Total Return IDP p.a. | Fund Inception |
---|---|---|---|---|---|
Barwon Healthcare Property Fund | $1.1351 | 6.04% | 0.82% | 6.86% | 10-Oct-14 |
The performance figures are net of taxes, fees and expenses and assuming distributions are reinvested. While reasonable care has been taken in the preparation of this content, Barwon Investment Partners Pty Limited ABN 19 116 012 009 AFSL 298445 makes no representation as to the accuracy or completeness of any statement in it, including without limitation, any forecasts. Past performance is not a reliable indicator of future performance.
How to Invest
The Zenith Investment Partners (ABN 27 103 132 672, AFS License 226872) (“Zenith”) rating (assigned December 2022) referred to in this piece is limited to “General Advice” (s766B Corporations Act 2001) for Wholesale clients only. This advice has been prepared without taking into account the objectives, financial situation or needs of any individual, including target markets of financial products, where applicable, and is subject to change at any time without prior notice. It is not a specific recommendation to purchase, sell or hold the relevant product(s). Investors should seek independent financial advice before making an investment decision and should consider the appropriateness of this advice in light of their own objectives, financial situation and needs. Investors should obtain a copy of, and consider the PDS or offer documents before making any decision and refer to the full Zenith Product Assessment available on the Zenith website. Past performance is not an indication of future performance. Zenith usually charges the product issuer, fund manager or related party to conduct Product Assessments. Full details regarding Zenith’s methodology, ratings definitions and regulatory compliance are available on our Product Assessments and at https://www.zenithpartners.com.au/our-solutions/investment-research/fund-research-regulatory-guidelines/.